Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only ...

CellCentric, a clinical-stage biotechnology company fighting blood cancer has onboarded Celia Economides as new CFO and Chief ...

CellCentric’s hope is that by targeting p300/CBP, inobrodib can lower the expression of MYC and IRF4, which are known to drive cancer. This potential has been enough to secure the biotech a $25 ...

The CD79B gene and other B cell-related genes >affected by ELOVL2 enzymatic activity (PAX5, IRF4) are frequently mutated or abnormally activated in lymphoid malignancies such as lymphoma and multiple ...

Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: A randomized, open label, phase II clinical trial. This is an ASCO ...

Note: Differences in patient/disease characteristics among groups (FL1-2, FL3A, FL3B and FL/DLBCL respectively) were analyzed using Fisher’s exact test for discrete variables and the Kruskal-Wallis H ...

This study provides new insights into the expression profile of ILCs that demonstrate a history of RAG expression. It examines in part the potential intrinsic regulation of RAG expression and seeks to ...

The Department of Medicine's Rheumatology Division is a world leader in the clinical care of patients with some of the most complex of all medical diseases, including rheumatoid arthritis, lupus, ...